Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer
NCT07781150 on ClinicalTrials.gov · last registry update 2026-08-24
Registered but not yet open, with 128 participants planned. Due to report 30 June 2029, alongside 11 other tracked readouts that quarter. Primary outcome, as filed: Complete response rate of endometrial lesions at 24 week. Sponsors move these dates routinely; any movement since this site started watching is listed below. mazdutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 1 time since then.
- Status
- NOT_YET_RECRUITING
- Phase
- P2
- Drug
- mazdutide
- Sponsor
- Tongji Hospital
- Sponsor type
- Other
- Enrollment
- 128
- Started
- 2026-11-01
- Primary completion
- 2029-06-30 estimated
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-08-24 | First seen in registry | Registered as NOT_YET_RECRUITING, P2 |
Primary outcome
Complete response rate of endometrial lesions at 24 week
Conditions studied
Obesity · Overweight · Atypical Endometrial Hyperplasia · Endometrial Carcinoma Stage I · Endometrioid Endometrial Cancer
Every field above is taken directly from the registry record. See all detected changes across the class, or the mazdutide page for this molecule’s full trial and approval history.